Therapy Area
Subcutaneous drugs grant a new lease on life to checkpoint inhibitors
The PD-1/PD-L1 inhibitor landscape is at the precipice of change with the approval of Roche’s subcutaneous formulation of Tecentriq.
Genmab receives EC approval for lymphoma therapy
Novartis eyes first-line status for its radionucleotide therapy Lutathera
China’s NMPA approves Henlius’ oesophageal cancer therapy
Valneva receives JE vaccine supply contract from US DoD
Merck and ICR enter renewed cancer drug discovery partnership
